AstraZeneca is working with startup Tremont AI to build AI models that flag potentially toxic drug candidates earlier in development, aiming to cut the cost and time lost to late-stage trial failures.
Personalis shareholders of record as of October 15 will soon vote on Tempus AI's all-stock acquisition, a deal that would fold Personalis' cancer genomics testing into Tempus' AI-driven oncology data platform.
Eli Lilly signed a roughly $1.1 billion AI drug delivery deal, separate from its earlier Insilico discovery partnership, extending AI across its pipeline.
Abridge closed a $316 million funding extension and added Eli Lilly as a strategic investor, pushing its AI scribe business deeper into billing automation.
Daniel Ek's Neko Health raised $700 million and opened its first US clinic in SoHo, betting that consumers will pay out of pocket for AI-driven preventive body scans.
AstraZeneca signed an AI drug-discovery deal with insitro on October 15, 2026 worth up to $1.5 billion, targeting MASH and cardiomyopathies using insitro's Virtual Human machine-learning platform.
Chai Discovery has raised a $400 million Series C round led by Index Ventures at a $3.8 billion valuation, nearly tripling its worth from seven months earlier as its AI-designed antibodies move into partnerships with Eli Lilly and Pfizer.
UpDoc's June FDA clearance as a patient-facing large language model opened new regulatory territory for AI that interacts directly with patients, a precedent other companies are now racing to replicate.
Insilico Medicine dosed the first patient in a trial for a candidate it says was discovered and designed using AI, a milestone in the race to prove computational drug discovery can produce viable therapeutics.
St. Luke's Health System has selected hellocare.ai to deploy AI-assisted virtual nursing, virtual sitting and connected-room technology across its southern Idaho hospitals, part of a fast-growing national push into enterprise virtual care.